FierceBiotech 21 ene 2026 Nkarta’s CEO wore head-to-toe pink at JPM. Here’s why it matters more than ever
FierceBiotech 20 ene 2026 Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years
FierceBiotech 20 ene 2026 Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs
FierceBiotech 20 ene 2026 Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis
FierceBiotech 20 ene 2026 Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark
FierceBiotech 20 ene 2026 Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
FierceBiotech 20 ene 2026 GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair
FierceBiotech 20 ene 2026 ARPA-H director eyes future beyond vaccines, ‘winning the biotech race’ against China
FierceBiotech 19 ene 2026 FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions
FierceBiotech 19 ene 2026 AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta
FierceBiotech 19 ene 2026 Immunology biotech Agomab, eye-focused SpyGlass are latest biotechs to share IPO ambitions
FierceBiotech 16 ene 2026 Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program